Global Endometriosis Market: Industry Analysis & Outlook (2018-2025)

February 2018 | 67 pages | ID: G24AE5897D1EN
Koncept Analytics

Abstracts

Endometriosis is a chronic condition which leads to severe symptoms if not diagnosed or treated on time. Cells, similar to the line of uterus known as endometrium start growing on the exteriors of uterus like fallopian tube, ovaries, and other internal parts. These tissues continue to act as it does and starts to thicken and breaks down and bleeds with each menstrual cycle and gets trapped, causing painful periods and severe pelvic pain.

The primary symptoms of endometriosis include fatigue, diarrhea, constipation, bloating and severe pain. Endometriosis has multiple treatment options but GnRH agonists have also shown high responder rates and thus believed to be the best in class therapeutics to treat endometriosis because three major drugs are in their final phase of successful clinical trials. These drugs are anticipated to change the complete market scenario with their launch.

The global endometriosis market is expected to experience robust growth post the launch of therapeutic drugs, primarily due to increasing patient base, rise in female population, and increasing healthcare expenditure. However, the market growth is hindered by high R&D expenditures and expensive drug costs.

The report “Global Endometriosis Market: Industry Analysis & Outlook (2018-2025)” analyzes the development of this market. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: AbbVie, Myovant Sciences, ObsEva SA, and Neurocrine Biosciences are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global endometriosis market along with the study of the regional markets.

Contents

1. MARKET OVERVIEW

1.1 Endometriosis
1.2 Symptoms
1.3 Causes
1.4 Treatment & Diagnosis

2. GLOBAL ENDOMETRIOSIS THERAPEUTIC MARKET ANALYSIS

2.1 Global Endometriosis Therapeutics Market by Prevalence
2.2 Global Endometriosis Therapeutics Market by Severity
2.3 Global Endometriosis Therapeutics Market Forecast by Value
2.4 Global Endometriosis Therapeutics Market Share Forecast by Drugs
2.5 Global Endometriosis Therapeutics Market Forecast by Drugs
  2.5.1 Global Elagolix Market Forecast by Value
  2.5.2 Global Relugolix Market Forecast by Value
  2.5.3 Global OBE2109 Market Forecast by Value

3. REGIONAL ENDOMETRIOSIS MARKET ANALYSIS

3.1 The US
  3.1.1 The US Population with Endometriosis-Forecast
  3.1.2 The US Population Seeking Treatment for Endometriosis-Forecast
  3.1.3 The US Population Diagnosed/Treated With Endometriosis-Forecast
3.2 Europe
  3.2.1 Europe’s Population Seeking Treatment for Endometriosis-Forecast
  3.2.2 Europe’s Population Diagnosed/Treated With Endometriosis-Forecast
  3.2.3 Europe’s Population Diagnosed/Treated With Moderate/Severe Endometriosis-Forecast

4. MARKET DYNAMICS

4.1 Growth Drivers
  4.1.1 Increasing Female Population Worldwide
  4.1.2 Intensifying Expenditure on Public Health Programs for Female
  4.1.3 Developing Endometriosis Market in Emerging Economies
  4.1.4 Increased Spending on Medicines
  4.1.5 Increasing Global Healthcare Expenditure
4.2 Trends and Developments
  4.2.1 Launch of Elagolix
  4.2.2 Development of New Drugs
  4.2.3 Improvement in Minimal and Non-Invasive Diagnostic Methods
  4.2.4 Expansion of More Efficient and Advanced Technology
4.3 Issues and Challenges
  4.3.1 High R&D Costs
  4.3.2 Drug Progress Challenges in Developing Countries
  4.3.3 High Cost of Drugs

5. COMPETITIVE LANDSCAPE

5.1 Revenue and Market Cap
5.2 Global Endometriosis Therapeutics Market
  5.2.1 Comparison of GnRH Antagonists in Development

6. COMPANY PROFILES

6.1 AbbVie Inc.
  6.1.1 Business Overview
  6.1.2 Financial Overview
  6.1.3 Business Strategies
6.2 ObsEva SA
  6.2.1 Business Overview
  6.2.2 Financial Overview
  6.2.3 Business Strategies
6.3 Neurocrine Biosciences
  6.3.1 Business Overview
  6.3.2 Financial Overview
  6.3.3 Business Strategies
6.4 Myovant Sciences Ltd.
  6.4.1 Business Overview
  6.4.2 Financial Overview
  6.4.2 Business Strategies

List Of Charts

LIST OF CHARTS

Endometriosis in Uterus
Potential Drug Candidates
Global Endometriosis Therapeutics Market by Severity (2017)
Global Endometriosis Therapeutics Market Forecast by Value (2018-2025)
Global Endometriosis Therapeutics Market Forecast by Drugs (2025)
Global Elagolix Market Forecast by Value (2018-2025)
Global Relugolix Market Forecast by Value (2020-2025)
Global OBE2109 Market Forecast by Value (2022-2025)
The US Population with Endometriosis-Forecast (2017-2025)
The US Population Seeking Treatment for Endometriosis-Forecast (2017-2025)
The US Population Diagnosed/Treated With Endometriosis-Forecast (2017-2025)
Europe’s Population Seeking Treatment for Endometriosis-Forecast (2017-2025)
Europe’s Population Diagnosed/Treated With Endometriosis-Forecast (2017-2025)
Europe’s Population Diagnosed/Treated With Moderate/Severe Endometriosis-Forecast (2017-2025)
Global Female Population (2013-2017)
Global Spending on Medicines (2010-2020E)
Total Spending on Medicines in the US (2013-2017)
Global Healthcare Expenditure (2013-3017)
AbbVie Inc. Revenue Share by Pharmaceutical Products (2017)
AbbVie Inc. Revenue and Net Earnings (2013-2017)
AbbVie Inc. Research and Development Expenditure (2016-2017)
ObsEva SA’s Net Income (2014-2017)
Neurocrine Biosciences Revenue (2013-2017)
Myovant Sciences Ltd.’s Net Loss (2016-2017)

List Of Tables

LIST OF TABLES

Current Endometriosis Standard of Care
Advantages and Drawbacks of Current Endometriosis Standard of Care
Global Endometriosis Therapeutics Market by Prevalence (2017)
Major Drugs for Endometriosis in their Development Phases (2017)
Market Cap & Revenue Comparison by Major Players (2017)
Comparison of GnRH Antagonists in Development for Endometriosis (2017)
Clinical Pipeline of Neurocrine Biosciences (2017)
ObsEva SA’s Product Pipeline (2017)
Myovant Sciences Ltd. Product Pipeline (2017)